PeptidePros

Compare · Head-to-head

AOD-9604 vs GHRP-2.

Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.

Which should you research first?

Start with AOD-9604, then use the table to confirm fit.

AOD-9604 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.

Comparison next step

Personalize this head-to-head.

Take the quiz before converting a comparison into a compound, vendor, or protocol decision.

01· Subject

AOD-9604

GH fragment studied in human obesity trials for lipolytic effects via β-adrenergic pathways.

Tier Bmed-high risk

02· Subject

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier Bhigh risk

01 · At a glance

Decision factorAOD-9604GHRP-2
Primary fitfat loss & metabolism research where you want a clear starting pointmuscle growth & strength and fat loss & metabolism comparisons
EvidenceTier BTier B
Riskmed-highhigh
Experience levelintermediateintermediate
Budget tiermidmid
Administration routeoral, subcutaneousintravenous, subcutaneous

02 · Use case & timing

Decision factorAOD-9604GHRP-2
Goal fitFat Loss & MetabolismMuscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization
What users compare it forModest lipolytic/fat loss signals in trials. Not equivalent to GLP-1 class.GH-axis stimulation; diagnostic use in some clinical settings.
Onset timelineClinical trials measured outcomes over ~12 weeks; weight loss signals modest.Acute hormone response within minutes to hours in stimulation tests.
Main tradeoffEvidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter.Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter.

03 · Safety & restrictions

Decision factorAOD-9604GHRP-2
Adverse effectsOverall tolerability similar to placebo in safety reports; some serious AEs in dose groups (judged unrelated by investigators).Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns.
ContraindicationsNo formal label.No formal label (not approved for consumer use).
Interaction notesMinimal established interactions.Endocrine spillover risks; avoid 'safe GH boost' framing.
Regulatory statusNot approvedNot approved
FDA flagFDA status unclearFDA status unclear
WADA statusWADA S2WADA S2

04 · Age & monitoring

Decision factorAOD-9604GHRP-2
Supported age rangesNo age guidance yetNo age guidance yet
Life-stage noteNot yet documentedNot yet documented
Monitoring burdenNot specifiedNot specified
Follow-up cadenceNot yet documentedNot yet documented

05 · Cost & sourcing

Decision factorAOD-9604GHRP-2
Typical cycle cost€963.31No reliable estimate yet
Estimated monthly cost€321.10No reliable estimate yet
Cost confidenceHigh confidenceNo estimate

06 · Before you buy

Decision factorAOD-9604GHRP-2
Tracked vendor listings2 listings0 listings
Sourcing noteTracked product pages are available, which makes it easier to review the listing before you click out.No tracked product page yet, so sourcing takes more manual review.
Stack-friendly?Usually stack-friendlyUsually stack-friendly

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Still deciding

Get a plan tailored to you.

The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.